Form 4: Immunovant CEO Sells Shares to Cover Tax Obligations After RSU Vesting

Immunovant CEO Peter Salzmann sold 28,094 shares of common stock on April 9, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On April 9, 2025, Peter Salzmann, CEO of Immunovant, Inc., sold 28,094 shares of Immunovant common stock.
• The sale was executed at a weighted average price of $12.99 per share, with individual transactions ranging from $12.75 to $13.26.
• This transaction was to cover tax withholding obligations associated with the vesting of 40,133 restricted stock units (RSUs) on April 2, 2025, which were part of a grant of 160,534 RSUs from April 2, 2024.
• The sale was mandated by Immunovant's policy requiring tax obligations to be met through a 'sell to cover' transaction, and was not a discretionary sale by Salzmann.
• Following the transaction, Salzmann still beneficially owns 1,186,512 shares of Immunovant common stock.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction related to executive compensation. It's neither particularly positive nor negative, as it's a standard practice.

Industry Context

Executive stock sales are common and often related to compensation and tax planning. The 'sell to cover' mechanism is a standard practice to manage tax obligations associated with equity compensation.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units (RSUs) as a way to align management's interests with those of shareholders.
• The 'sell to cover' practice is a common method used by companies to simplify the tax obligations for employees receiving equity compensation.
• Comparing Immunovant's executive compensation structure and stock ownership with those of similar biotechnology companies (e.g., Argenx, UCB, or Johnson & Johnson following their acquisition of Horizon Therapeutics) would provide a broader context.

Stakeholder Impact

• The stock sale could have a minor, temporary impact on the stock price, but is unlikely to have a significant long-term effect.
• The transaction ensures the CEO remains compliant with tax regulations related to equity compensation.

Key Dates

Keywords

Immunovant, Peter Salzmann, IMVT, stock sale, restricted stock units, RSUs, tax withholding, Form 4, CEO, beneficial ownership